Physicians' Academy for Cardiovascular Education

EAS 2021

News from the virtual EAS 2021 congress, May 31-June 2.

Increased atherogenicity of LDL and impaired HDL function in children with FH

News - June 7, 2021

EAS 2021 This study showed that children with familiar hypercholesterolemia had an increased susceptibility of LDL particles to form aggregates and a reduced cholesterol efflux capacity of HDL compared to healthy children.

Larger gap between guidelines and clinical practice for LDL-c management in East-Central Europe

News - June 3, 2021

EAS 2021 This DA VINCI subanalysis showed that the proportion of patients achieving their risk-based LDL-c goal using the 2016 and 2019 ESC/EAS guidelines in patients on lipid lowering therapy for primary and secondary care was lower in Central- and East- Europe than in North- or West-Europe.

Registry study shows large reduction of clinical outcomes by lipoprotein apheresis

News - June 3, 2021

EAS 2021 An analysis of data from the German Lipoprotein Apheresis Registry (GLAR) from 2012-2020 demonstrated substantial lowering of MACE and major non-coronary events within two years of initiation of lipoprotein apheresis.

Real-world data of PCSK9i use in FH patients

News - June 2, 2021

EAS 2021 An interim-analysis of the HEYMANS study showed that the majority of FH (both HeFH and HoFH) patients have a history of CV events and comorbidities. Initiation of evolocumab in these patients resulted in reduced LDL-c levels, maintained throughout the study.

Safety of PCSK9 siRNA demonstrated in pooled data analysis

News - June 1, 2021

EAS 2021 A pooled data analysis of ORION-9, 10 and 11 showed no changes in hematological and immunological biomarkers in patients with ASCVD or risk equivalent treated with inclisiran over a treatment period of 540 days.